Literature DB >> 17975676

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

Antonius E van Herwaarden1, Els Wagenaar, Cornelia M M van der Kruijssen, Robert A B van Waterschoot, Johan W Smit, Ji-Ying Song, Martin A van der Valk, Olaf van Tellingen, José W A van der Hoorn, Hilde Rosing, Jos H Beijnen, Alfred H Schinkel.   

Abstract

Cytochrome P450 3A (CYP3A) enzymes constitute an important detoxification system that contributes to primary metabolism of more than half of all prescribed medications. To investigate the physiological and pharmacological roles of CYP3A, we generated Cyp3a-knockout (Cyp3a-/-) mice lacking all functional Cyp3a genes. Cyp3a-/- mice were viable, fertile, and without marked physiological abnormalities. However, these mice exhibited severely impaired detoxification capacity when exposed to the chemotherapeutic agent docetaxel, displaying higher exposure levels in response to both oral and intravenous administration. These mice also demonstrated increased sensitivity to docetaxel toxicity, suggesting a primary role for Cyp3a in xenobiotic detoxification. To determine the relative importance of intestinal versus hepatic Cyp3a in first-pass metabolism, we generated transgenic Cyp3a-/- mice expressing human CYP3A4 in either the intestine or the liver. Expression of CYP3A4 in the intestine dramatically decreased absorption of docetaxel into the bloodstream, while hepatic expression aided systemic docetaxel clearance. These results suggest that CYP3A expression determines impairment of drug absorption and efficient systemic clearance in a tissue-specific manner. The genetic models used in this study provide powerful tools to further study CYP3A-mediated xenobiotic metabolism, as well as interactions between CYP3A and other detoxification systems.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975676      PMCID: PMC2045619          DOI: 10.1172/JCI33435

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

Authors:  Heleen A Bardelmeijer; Mariët Ouwehand; Tessa Buckle; Maarten T Huisman; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

2.  Corticosterone 6 beta-hydroxylase in A6 epithelia: a steroid-inducible cytochrome P-450.

Authors:  W M Grogan; V M Phillips; E G Schuetz; P S Guzelian; C O Watlington
Journal:  Am J Physiol       Date:  1990-03

Review 3.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

Authors:  V J Wacher; C Y Wu; L Z Benet
Journal:  Mol Carcinog       Date:  1995-07       Impact factor: 4.784

Review 4.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

5.  Megabase deletions of gene deserts result in viable mice.

Authors:  Marcelo A Nóbrega; Yiwen Zhu; Ingrid Plajzer-Frick; Veena Afzal; Edward M Rubin
Journal:  Nature       Date:  2004-10-21       Impact factor: 49.962

6.  Hormonal regulation of the zonated expression of cytochrome P-450 3A in rat liver.

Authors:  T Oinonen; K O Lindros
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

7.  Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.

Authors:  F Marre; G J Sanderink; G de Sousa; C Gaillard; M Martinet; R Rahmani
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

8.  P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate.

Authors:  M Kitada; T Kamataki; K Itahashi; T Rikihisa; Y Kanakubo
Journal:  J Biol Chem       Date:  1987-10-05       Impact factor: 5.157

9.  CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.

Authors:  Raymond C Givens; Yvonne S Lin; Amy L S Dowling; Kenneth E Thummel; Jatinder K Lamba; Erin G Schuetz; Paul W Stewart; Paul B Watkins
Journal:  J Appl Physiol (1985)       Date:  2003-05-16

Review 10.  Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.

Authors:  David R Nelson; Darryl C Zeldin; Susan M G Hoffman; Lois J Maltais; Hester M Wain; Daniel W Nebert
Journal:  Pharmacogenetics       Date:  2004-01
View more
  57 in total

1.  A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.

Authors:  Stacy Moulder; Gregory Gladish; Joe Ensor; Ana Maria Gonzalez-Angulo; Massimo Cristofanilli; James L Murray; Daniel Booser; Sharon H Giordano; Abeena Brewster; Julia Moore; Edgardo Rivera; Gabriel N Hortobagyi; Hai T Tran
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

Review 2.  Pregnane X receptor- and CYP3A4-humanized mouse models and their applications.

Authors:  Jie Cheng; Xiaochao Ma; Frank J Gonzalez
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

3.  Gut instincts: CYP3A4 and intestinal drug metabolism.

Authors:  Kenneth E Thummel
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

4.  Role of CYP3A in isoniazid metabolism in vivo.

Authors:  Ke Liu; Feng Li; Jie Lu; Zhiwei Gao; Curtis D Klaassen; Xiaochao Ma
Journal:  Drug Metab Pharmacokinet       Date:  2013-10-29       Impact factor: 3.614

5.  Contributions of the three CYP1 monooxygenases to pro-inflammatory and inflammation-resolution lipid mediator pathways.

Authors:  Senad Divanovic; Jesmond Dalli; Lucia F Jorge-Nebert; Christopher L Karp; Charles N Serhan; Daniel W Nebert; Leah M Flick; Marina Gálvez-Peralta; Nicholas D Boespflug; Traci E Stankiewicz; Jonathan M Fitzgerald; Maheshika Somarathna
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

6.  Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.

Authors:  Shuiying Hu; Zhaoyuan Chen; Ryan Franke; Shelley Orwick; Ming Zhao; Michelle A Rudek; Alex Sparreboom; Sharyn D Baker
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

7.  Cimetidine-associated patent ductus arteriosus is mediated via a cytochrome P450 mechanism independent of H2 receptor antagonism.

Authors:  Robert B Cotton; Lisa P Shah; Stanley D Poole; Noah J Ehinger; Naoko Brown; Elaine L Shelton; James C Slaughter; H Scott Baldwin; Bibhash C Paria; Jeff Reese
Journal:  J Mol Cell Cardiol       Date:  2013-02-27       Impact factor: 5.000

8.  Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice.

Authors:  Susan F Hudachek; Daniel L Gustafson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-04-25       Impact factor: 2.745

9.  Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes.

Authors:  Robert A B van Waterschoot; Antonius E van Herwaarden; Jurjen S Lagas; Rolf W Sparidans; Els Wagenaar; Cornelia M M van der Kruijssen; Joyce A Goldstein; Darryl C Zeldin; Jos H Beijnen; Alfred H Schinkel
Journal:  Mol Pharmacol       Date:  2007-12-21       Impact factor: 4.436

10.  An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal p450s in first-pass clearance of oral nifedipine.

Authors:  Qing-Yu Zhang; Cheng Fang; Jin Zhang; Deborah Dunbar; Laurence Kaminsky; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2008-12-04       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.